Three-day therapy of vaginal candidiasis with clotrimazole vaginal tablets and econazole ovules: a multicentre comparative study.
The activity and tolerance of 200 mg clotrimazole vaginal tablets and 150 mg econazole vaginal ovules were compared in the treatment of vaginal candidiasis in a controlled multicentre (3 centres) study. Treatment was allocated according to a randomized list and each investigator treated 20 patients per group. The duration of therapy was 3 days. Follow-up investigations were carried out approximately 1 week and 4 weeks after commencement of treatment. The results were analyzed for 54 patients treated with clotrimazole and 57 with econazole: 9 patients were excluded from the analysis because of insufficient data. At the first follow-up examination, 1 week after starting therapy, 93.7% of patients on clotrimazole and 83.7% of patients on econazole had negative cultures. The success of therapy, as judged by the clinicians, was 95.8% for clotrimazole and 88.0% for econazole. For the first and fourth week combined reviews, 86.0% of clotrimazole patients and 77.8% of econazole patients had negative cultures and the success of therapy was 88.4% for clotrimazole and 80.0% for econazole. These differences were not statistically significant but there was a clear numerical superiority for clotrimazole. Tolerance was good in all the patients and no side-effects were observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002181:Candidiasis, Vulvovaginal / Q000150:complications / Q000188:drug therapy*; D003022:Clotrimazole / Q000008:administration & dosage*; D004464:Econazole / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008875:Middle Aged; D013488:Suppositories; D013607:Tablets; D014621:Vagina
D007093:Imidazoles; D013488:Suppositories; D013607:Tablets; D004464:Econazole; D003022:Clotrimazole